select a format

Single User License
USD 2000 INR 130060
Site License
USD 4000 INR 260120
Corporate User License
USD 6000 INR 390180

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Dyskinesia-Pipeline Review, H2 2017

Dyskinesia-Pipeline Review, H2 2017


  • Products Id :- GMDHC9708IDB
  • |
  • Pages: 147
  • |
  • September 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Dyskinesia-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia-Pipeline Review, H2 2017, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape.

Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyskinesia-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 13, 4, 17 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Dyskinesia (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Dyskinesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Dyskinesia (Central Nervous System)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Dyskinesia (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Dyskinesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 7

Global Markets Direct Report Coverage 7

Dyskinesia-Overview 8

Dyskinesia-Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 17

Dyskinesia-Therapeutics Assessment 18

Assessment by Target 18

Assessment by Mechanism of Action 21

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Dyskinesia-Companies Involved in Therapeutics Development 28

Adamas Pharmaceuticals Inc 28

Addex Therapeutics Ltd 28

Advicenne SA 29

Avanir Pharmaceuticals Inc 29

Bionomics Ltd 29

Catalyst Biosciences Inc 30

Cavion LLC 30

Clevexel Pharma SAS 31

EpiVax Inc 31

Heptares Therapeutics Ltd 31

Ipsen SA 32

Merz Pharma GmbH & Co KgaA 32

Neurim Pharmaceuticals Ltd 33

Neurocrine Biosciences Inc 33

Neurolixis Inc 33

Osmotica Pharmaceutical Corp 34

Phenomenome Discoveries Inc 34

Sage Therapeutics Inc 35

SciFluor Life Sciences LLC 35

SOM Biotech SL 35

Synchroneuron Inc 36

Dyskinesia-Drug Profiles 37

(dextromethorphan + quinidine sulfate)-Drug Profile 37

A-2M13677-Drug Profile 42

abobotulinumtoxinA-Drug Profile 43

acamprosate calcium SR-Drug Profile 47

amantadine hydrochloride ER-Drug Profile 49

amantadine hydrochloride ER-Drug Profile 59

AT-127-Drug Profile 60

AT-326-Drug Profile 61

AT-403-Drug Profile 62

befiradol-Drug Profile 63

brexanolone-Drug Profile 65

CVXL-0107-Drug Profile 74

CX-8998-Drug Profile 75

cycloserine-Drug Profile 76

dipraglurant IR-Drug Profile 77

Drug for Dyskinesia-Drug Profile 82

Drug for Tardive Dyskinesia-Drug Profile 83

Drugs for Dyskinesia-Drug Profile 84

Gene Therapy to Inhibit TRH for Dyskinesia-Drug Profile 85

HTL-14242-Drug Profile 86

incobotulinumtoxin A-Drug Profile 87

IRL-790-Drug Profile 92

JM-010-Drug Profile 93

MLR-1019-Drug Profile 95

NBI-640756-Drug Profile 96

Neu-120-Drug Profile 97

Neu-240-Drug Profile 98

onabotulinumtoxinA-Drug Profile 99

PCT-3010-Drug Profile 100

PPI-1011-Drug Profile 101

RNAi Gene Therapy to Inhibit NURR1 for Dyskinesia-Drug Profile 102

SAGE-217-Drug Profile 103

SK-609-Drug Profile 107

Small Molecule for Dyskinesia-Drug Profile 108

Small Molecule for Dyskinesia-Drug Profile 109

Small Molecules for Neurodegenerative Disease-Drug Profile 110

Small Molecules to Antagonize GPCR for Central Nervous System Diseases-Drug Profile 111

Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia-Drug Profile 112

Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders-Drug Profile 113

Small Molecules to Antagonize mGluR5 for Dyskinesia-Drug Profile 114

Small Molecules to Target Ion Channels for CNS Disorders-Drug Profile 115

SOM-3355-Drug Profile 116

TC-8831-Drug Profile 117

tetrabenazine-Drug Profile 118

valbenazine tosylate-Drug Profile 119

Dyskinesia-Dormant Projects 127

Dyskinesia-Discontinued Products 129

Dyskinesia-Product Development Milestones 130

Featured News & Press Releases 130

Appendix 143

Methodology 143

Coverage 143

Secondary Research 143

Primary Research 143

Expert Panel Validation 143

Contact Us 143

Disclaimer 144

List of Figures

Number of Products under Development for Dyskinesia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

List of Tables

Number of Products under Development for Dyskinesia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Dyskinesia-Pipeline by Adamas Pharmaceuticals Inc, H2 2017

Dyskinesia-Pipeline by Addex Therapeutics Ltd, H2 2017

Dyskinesia-Pipeline by Advicenne SA, H2 2017

Dyskinesia-Pipeline by Avanir Pharmaceuticals Inc, H2 2017

Dyskinesia-Pipeline by Bionomics Ltd, H2 2017

Dyskinesia-Pipeline by Catalyst Biosciences Inc, H2 2017

Dyskinesia-Pipeline by Cavion LLC, H2 2017

Dyskinesia-Pipeline by Clevexel Pharma SAS, H2 2017

Dyskinesia-Pipeline by EpiVax Inc, H2 2017

Dyskinesia-Pipeline by Heptares Therapeutics Ltd, H2 2017

Dyskinesia-Pipeline by Ipsen SA, H2 2017

Dyskinesia-Pipeline by Merz Pharma GmbH & Co KgaA, H2 2017

Dyskinesia-Pipeline by Neurim Pharmaceuticals Ltd, H2 2017

Dyskinesia-Pipeline by Neurocrine Biosciences Inc, H2 2017

Dyskinesia-Pipeline by Neurolixis Inc, H2 2017

Dyskinesia-Pipeline by Osmotica Pharmaceutical Corp, H2 2017

Dyskinesia-Pipeline by Phenomenome Discoveries Inc, H2 2017

Dyskinesia-Pipeline by Sage Therapeutics Inc, H2 2017

Dyskinesia-Pipeline by SciFluor Life Sciences LLC, H2 2017

Dyskinesia-Pipeline by SOM Biotech SL, H2 2017

Dyskinesia-Pipeline by Synchroneuron Inc, H2 2017

Dyskinesia-Dormant Projects, H2 2017

Dyskinesia-Dormant Projects, H2 2017 (Contd..1), H2 2017

Dyskinesia-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Adamas Pharmaceuticals Inc

Addex Therapeutics Ltd

Advicenne SA

Avanir Pharmaceuticals Inc

Bionomics Ltd

Catalyst Biosciences Inc

Cavion LLC

Clevexel Pharma SAS

EpiVax Inc

Heptares Therapeutics Ltd

Ipsen SA

Merz Pharma GmbH & Co KgaA

Neurim Pharmaceuticals Ltd

Neurocrine Biosciences Inc

Neurolixis Inc

Osmotica Pharmaceutical Corp

Phenomenome Discoveries Inc

Sage Therapeutics Inc

SciFluor Life Sciences LLC

SOM Biotech SL

Synchroneuron Inc

Dyskinesia Therapeutic Products under Development, Key Players in Dyskinesia Therapeutics, Dyskinesia Pipeline Overview, Dyskinesia Pipeline, Dyskinesia Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com